[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548965":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":40,"collaborators":26,"id":44,"slug":26,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":26,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":26,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":26,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":26},{"fullName":5,"class":6},"Ramathibodi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical tranexamic acid (TXA) injection","EXPERIMENTAL","receive an injection of topical tranexamic acid (TXA) into the surgical site",[13],"Drug: Tranexamic acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","receive an injection Normal saline into the surgical site",[19],"Drug: Normal saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tranexamic acid","receive an injection of Tranexamic acid into the surgical site",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal saline","receive an injection of Normal saline into the surgical site",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Thanawan Longsuwan, Doctor of medicine","CONTACT","(+66)892966855","bland.demon3@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":26},"Kan Kaewroj, Diploma of Orthopaedics","(+66) 022011589",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Thanawan Longsuwan","Doctor","100548965",false,"NCT06427850","Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF)","Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF): A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 30-80 years old\n* Degenerative spine problems including spinal stenosis, disc degeneration, spondylolithesis that indicated for single level MI-TLIF\n\nExclusion Criteria:\n\n* Revision surgery\n* Patients who had high risk of complication from TXA\n* History of seizure, PE, DVT, thromboembolic episode\n* History of TXA allergy\n* Patients who had high risk for bleeding\n* U\u002FD : CKD stage more than IIIb (GFR\\\u003C 45 ml\u002Fmin\u002F1.73m2), hepatic disease, bleeding disorder\n* On anticoagulation drug or antiplatelet drug in 7 days before surgery\n* Abnormal coagulation profile (INR \\> 1.5) or CBC (platelet \\\u003C 100000)",true,"ALL","30 Years","80 Years",{"count":55,"type":56},28,"ESTIMATED","INTERVENTIONAL",[59],"NA","The randomized controlled study which compare the efficacy outcomes (reducing blood loss and drainage output in patients) in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) and received topical tranexamic acid injection in the surgical site to those who received placebo injection.",[62,63],"Degenerative Spine Diseases","Surgical Wound",[65,66,67],"Degenerative spine diseases","Surgical wound","Tranexamic acid (TXA)","NOT_YET_RECRUITING","2024-05-20",{"date":71,"type":72},"2024-05-24","ACTUAL",{"date":74,"type":56},"2024-07-01",{"date":76,"type":56},"2026-12-01",{"name":42,"class":6}]